Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study - The Lancet Regional Health – Europe
Plug and Play” mRNA technology works fast, updating vaccines in months : Oregon Health News Blog
Vaccines | Free Full-Text | Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients
Does a second monovalent SARS-CoV-2 mRNA booster increase neutralizing activity to Omicron variants in nursing home residents and healthcare workers?
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial - The Lancet
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa: Molecular Therapy
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar | NEJM
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination | NEJM
Data suggests mRNA booster dose generates stronger antibody response after J&J shot - Axios | Reuters
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial - The Lancet Infectious Diseases
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants | NEJM
Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study - The Lancet Respiratory Medicine
Investigating effectiveness of mRNA booster against SARS-CoV-2 Omicron in individuals primed with mRNA or inactivated virus vaccines
COVID-19 mRNA booster provides additional protection, most beneficial for older adults
Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults - The Lancet Infectious Diseases
Pfizer (PFE), Moderna (MRNA) Covid Booster Vaccines Greenlighted by CDC Panel - Bloomberg
CDC on X: "CDC recommends Novavax's non-mRNA booster for people ages 18+, for certain situations. This includes those unable or unwilling to receive mRNA #COVID19 vaccines. The Novavax COVID-19 booster targets the
Three mRNA COVID-19 vaccine doses very effective in protecting against emergency department visits and hospitalizations associated with Omicron and Delta variants
Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study | The BMJ
Boosting with updated COVID-19 mRNA vaccines | Nature Medicine
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2 | Nature Communications
Moderna on X: "A 50 µg #booster dose of our first bivalent booster #vaccine candidate, mRNA-1273.211, demonstrated superiority against Beta, Delta and #Omicron variants of concern one month after administration, and superiority
Study highlights the importance of bivalent mRNA booster vaccination in populations at high risk of severe COVID-19
Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022 | MMWR
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR
